PDCD1 and neoplasm: Emerging data indicated that traditional single drug treatment is not sufficient for improving the progression-free survival of patients with tumor, and the efficacy of therapy in combination with anti-CTLA4, anti-PD1, or anti-PDL1 antibodies, as well as with other immunotherapies, chemotherapies, radiation therapies, and targeted therapies is better than that of treatment with single drug.